Biolase Stock Buy Hold or Sell Recommendation
| BIOL Stock | USD 0.15 0.01 7.14% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding BIOLASE is 'Strong Sell'. Macroaxis provides BIOLASE buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BIOLASE positions. The advice algorithm takes into account all of BIOLASE's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting BIOLASE's buy or sell advice are summarized below:
Real Value 5.67 | Target Price 22.25 | Hype Value 0.17 | Market Value 0.15 | Naive Value 0.19 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell BIOLASE given historical horizon and risk tolerance towards BIOLASE. When Macroaxis issues a 'buy' or 'sell' recommendation for BIOLASE, the advice is generated through an automated system that utilizes algorithms and statistical models.
BIOLASE |
Execute BIOLASE Buy or Sell Advice
The BIOLASE recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on BIOLASE. Macroaxis does not own or have any residual interests in BIOLASE or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute BIOLASE's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
BIOLASE Trading Alerts and Improvement Suggestions
| BIOLASE generated a negative expected return over the last 90 days | |
| BIOLASE has high historical volatility and very poor performance | |
| BIOLASE has some characteristics of a very speculative penny stock | |
| BIOLASE has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 49.16 M. Net Loss for the year was (20.63 M) with profit before overhead, payroll, taxes, and interest of 16.53 M. | |
| BIOLASE currently holds about 9.96 M in cash with (14.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| BIOLASE has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: StockNews.com Initiates Coverage on BIOLASE - Defense World |
BIOLASE Returns Distribution Density
The distribution of BIOLASE's historical returns is an attempt to chart the uncertainty of BIOLASE's future price movements. The chart of the probability distribution of BIOLASE daily returns describes the distribution of returns around its average expected value. We use BIOLASE price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of BIOLASE returns is essential to provide solid investment advice for BIOLASE.
| Mean Return | -2.01 | Value At Risk | -13.59 | Potential Upside | 14.29 | Standard Deviation | 11.35 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of BIOLASE historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
BIOLASE Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BIOLASE is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BIOLASE backward and forwards among themselves. BIOLASE's institutional investor refers to the entity that pools money to purchase BIOLASE's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2023-12-31 | 18.0 | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 14.0 | Huntington National Bank | 2023-12-31 | 1.0 | Perkins Capital Management Inc | 2023-09-30 | 0.0 | Honkamp Krueger Financial Services Inc | 2023-09-30 | 0.0 | Walleye Trading Advisors, Llc | 2023-12-31 | 0.0 | Corecap Advisors, Llc | 2023-09-30 | 0.0 | Anson Funds Management Lp | 2023-12-31 | 185.1 K | Blackrock Inc | 2023-12-31 | 25 K | Kellett Schaffner Wealth Advisors Llc | 2023-12-31 | 19.1 K | Zhang Financial Llc | 2023-12-31 | 13.8 K |
BIOLASE Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 840K | (871K) | (1.4M) | (5.8M) | 969K | 1.0M | |
| Change In Cash | (2.3M) | 11.8M | 12.3M | (26.0M) | 2.4M | 2.5M | |
| Free Cash Flow | (13.0M) | (12.9M) | (17.4M) | (30.5M) | (15.4M) | (14.6M) | |
| Depreciation | 982K | 499K | 400K | 497K | 2.8M | 2.9M | |
| Other Non Cash Items | 2.5M | 496K | 994K | 4.1M | 805.0K | 994.7K | |
| Capital Expenditures | 207K | 96K | 707K | 3.7M | 1.3M | 837.2K | |
| Net Income | (17.9M) | (16.8M) | (16.2M) | (28.6M) | (20.6M) | (19.6M) | |
| End Period Cash Flow | 6.1M | 17.9M | 30.2M | 4.2M | 6.6M | 7.9M | |
| Change Receivables | (337K) | (1.5M) | 655K | 4.3M | 4.9M | 5.2M | |
| Net Borrowings | 11.4M | 2.4M | 2.4M | (1M) | (1.2M) | (1.1M) | |
| Change To Netincome | 4.9M | (356K) | (1.5M) | 5.3M | 4.7M | 5.0M | |
| Investments | (207K) | (96K) | (707K) | (3.7M) | (1.6M) | (1.7M) |
BIOLASE Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BIOLASE or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BIOLASE's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BIOLASE stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -2.37 | |
β | Beta against NYSE Composite | 4.41 | |
σ | Overall volatility | 11.57 | |
Ir | Information ratio | -0.18 |
BIOLASE Volatility Alert
BIOLASE is displaying above-average volatility over the selected time horizon. BIOLASE is a potential penny stock. Although BIOLASE may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in BIOLASE. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on BIOLASE instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.BIOLASE Fundamentals Vs Peers
Comparing BIOLASE's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze BIOLASE's direct or indirect competition across all of the common fundamentals between BIOLASE and the related equities. This way, we can detect undervalued stocks with similar characteristics as BIOLASE or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of BIOLASE's fundamental indicators could also be used in its relative valuation, which is a method of valuing BIOLASE by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare BIOLASE to competition |
| Fundamentals | BIOLASE | Peer Average |
| Return On Equity | -6.03 | -0.31 |
| Return On Asset | -0.29 | -0.14 |
| Profit Margin | (0.42) % | (1.27) % |
| Operating Margin | (0.35) % | (5.51) % |
| Current Valuation | 16.22 M | 16.62 B |
| Shares Outstanding | 33.26 M | 571.82 M |
| Shares Owned By Insiders | 0.33 % | 10.09 % |
| Shares Owned By Institutions | 8.23 % | 39.21 % |
| Number Of Shares Shorted | 2.29 M | 4.71 M |
| Price To Earning | (7.23) X | 28.72 X |
| Price To Book | 0.77 X | 9.51 X |
| Price To Sales | 0.1 X | 11.42 X |
| Revenue | 49.16 M | 9.43 B |
| Gross Profit | 16.53 M | 27.38 B |
| EBITDA | (15.14 M) | 3.9 B |
| Net Income | (20.63 M) | 570.98 M |
| Cash And Equivalents | 9.96 M | 2.7 B |
| Cash Per Share | 1.39 X | 5.01 X |
| Total Debt | 17.91 M | 5.32 B |
| Debt To Equity | 1.07 % | 48.70 % |
| Current Ratio | 2.46 X | 2.16 X |
| Book Value Per Share | (0.07) X | 1.93 K |
| Cash Flow From Operations | (14.09 M) | 971.22 M |
| Short Ratio | 0.21 X | 4.00 X |
| Earnings Per Share | (29.44) X | 3.12 X |
| Price To Earnings To Growth | (0.22) X | 4.89 X |
| Target Price | 11.22 | |
| Number Of Employees | 157 | 18.84 K |
| Beta | 0.69 | -0.15 |
| Market Capitalization | 4.99 M | 19.03 B |
| Total Asset | 35.1 M | 29.47 B |
| Retained Earnings | (316.8 M) | 9.33 B |
| Working Capital | 5.2 M | 1.48 B |
Note: Disposition of 1395 shares by Jonathan Lord of BIOLASE subject to Rule 16b-3 [view details]
BIOLASE Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as BIOLASE . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About BIOLASE Buy or Sell Advice
When is the right time to buy or sell BIOLASE? Buying financial instruments such as BIOLASE Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 15.1M | 15.1M | 17.9M | 18.8M | Total Assets | 55.3M | 38.2M | 35.1M | 31.3M |
Use Investing Ideas to Build Portfolios
In addition to having BIOLASE in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Printing and Publishing Thematic Idea Now
Printing and Publishing
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Printing and Publishing theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Printing and Publishing Theme or any other thematic opportunities.
| View All Next | Launch |
Check out BIOLASE Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy BIOLASE Stock please use our How to buy in BIOLASE Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for BIOLASE Stock analysis
When running BIOLASE's price analysis, check to measure BIOLASE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BIOLASE is operating at the current time. Most of BIOLASE's value examination focuses on studying past and present price action to predict the probability of BIOLASE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BIOLASE's price. Additionally, you may evaluate how the addition of BIOLASE to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |
Is BIOLASE's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BIOLASE. If investors know BIOLASE will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BIOLASE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (29.44) | Revenue Per Share 38.469 | Quarterly Revenue Growth (0.04) | Return On Assets (0.29) | Return On Equity (6.03) |
The market value of BIOLASE is measured differently than its book value, which is the value of BIOLASE that is recorded on the company's balance sheet. Investors also form their own opinion of BIOLASE's value that differs from its market value or its book value, called intrinsic value, which is BIOLASE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BIOLASE's market value can be influenced by many factors that don't directly affect BIOLASE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BIOLASE's value and its price as these two are different measures arrived at by different means. Investors typically determine if BIOLASE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BIOLASE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.